MEDANTA Global Health Q4 FY25 results (Jan–Mar 2025) and concall
Global Health (Medanta) delivered a steady FY25 performance characterized by double-digit revenue growth and strong margins in its developing units. The company is entering an aggressive growth phase, planning to double its bed capacity to ~6,000 beds via a ₹4,000 crore capex program. Management remains confident in the ramp-up of new facilities like Noida and Ranchi while maintaining healthy cash surpluses to fund expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 665 | 812 | 803 |
| EBITDA | 150 | 202 | 195 |
| Net profit | 104 | 131 | 93 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
